Rate My Professor Michael Winder

Winder's academic interests focus on the pharmacology of inflammatory conditions in the lower urinary tract, including the impacts of signaling molecules like nitric oxide and pharmacological agents. He explores prostate-to-bladder cross-sensitization in prostatitis, purinergic and muscarinic signaling in the urinary bladder, and glandular secretory processes. Projects he leads encompass the role of nitric oxide in the lower urinary tract, connections between bladder dysfunction and chronic prostatitis, secretory mechanisms in lacrimal and salivary glands, and cannabinoid applications in prostate cancer. With over 56 publications and more than 540 citations, his contributions feature in outlets such as Scientific Reports, JCI Insight, Frontiers in Physiology, BMC Urology, and Pharmacology Research & Perspectives. Select publications are 'Induction of chronic prostatitis does not alter the innate immune response in the rat urinary bladder' (2025), 'Vagal oxytocin receptors are necessary for esophageal-motivated feeding' (2025), 'Soluble guanylate cyclase mediates the relaxation of cyclophosphamide-treated rat urinary bladder' (2023), 'Cross-organ sensitization between the prostate and bladder in prostatitis' (2021), and 'Combination drug therapy against OAB normalizes micturition contractions and voiding pattern in a rat model of cystitis' (2020). He participates in international forums like the International Continence Society.